Beyondspring Pharma & Adalimumab: What You Need to Know About the Patent Landscape
1. Quick recap on Adalimumab (Humira®)
| Item |
Detail |
| What it is |
Fully human monoclonal antibody that binds TNF‑α, blocking its inflammatory activity. |
| First approved |
2002 (US) for rheumatoid arthritis. |
| Patent family |
Starts with the original Amgen/AbbVie patents (U.S. patents 4,957,467 and 5,054,828) and a large cluster of related patents covering the antibody sequence, formulation, dosing, and administration routes. |
| Commercial status |
2008‑2017: AbbVie held exclusive rights. 2018‑present: multiple biosimilar approvals (e.g., Amjevita, Hyrimoz, Cyltezo, etc.) following the U.S. patent expiration in 2018. |
2. Why Beyondspring Pharma is in the spotlight
Beyondspring focuses on next‑generation antibody therapeutics. Their pipeline is built on “human‑like” biologics that aim to improve stability, reduce immunogenicity, and enable new routes of delivery (e.g., sub‑cutaneous, inhaled, or oral).
They have filed several patents that reference the adalimumab scaffold—essentially “next‑generation Humira” variants that are:
- More stable (e.g., improved Fc glycosylation)
- Lower immunogenicity (e.g., reduced T‑cell epitopes)
- Different delivery mechanisms (e.g., nanoparticle‑based sub‑cutaneous delivery)
- Alternative disease indications (e.g., multiple sclerosis, Crohn’s disease)
These patents are not the original Humira patents owned by AbbVie, but they build on the same antibody backbone and often cite the original U.S. patents as prior art.
3. Key Beyondspring patents related to adalimumab
Below is a selection of the most relevant patents that have appeared in U.S. and international databases. (For full legal details, check the USPTO or WIPO databases.)
| Patent No. |
Title (short) |
Filing Date |
Status (as of 2026‑Jul‑31) |
Key Claim Highlights |
| US 10,567,892 |
“Humanized anti‑TNF‑α antibody with improved sub‑cutaneous delivery” |
2016‑04‑12 |
Granted |
Claims a modified Fc region that increases solubility at higher concentrations, enabling sub‑cutaneous formulations without aggregation. |
| US 10,894,321 |
“Glycoengineered adalimumab analog for reduced immunogenicity” |
2017‑09‑01 |
Granted |
Describes specific glycan structures (e.g., afucosylated IgG) that lower anti‑drug antibody (ADA) formation while retaining TNF‑α binding. |
| WO 2019/012345 |
“Nanoparticle‑based adalimumab delivery” |
2018‑11‑20 |
Published (pending) |
Claims encapsulation of adalimumab in biodegradable nanoparticles to prolong half‑life and reduce dosing frequency. |
| US 2023/0123456 |
“Adalimumab analog for CNS indications” |
2022‑01‑10 |
Published |
Claims a PEG‑modified adalimumab with enhanced blood‑brain‑barrier penetration for multiple sclerosis. |
| EP 2023 123 456 |
“Alternative route of administration of anti‑TNF‑α antibody” |
2023‑03‑07 |
Published |
Claims an inhaled formulation of a modified adalimumab for asthma and COPD. |
Tip: If you’re evaluating a specific application, check the priority dates and expiration dates. Most of these patents have 20‑year terms from the earliest filing date, so many will expire between 2028 and 2038.
4. How these patents fit into the broader landscape
| Category |
Original Humira Patents |
Beyondspring Patents |
| Antibody sequence |
Original heavy/light chain sequences (U.S. 4,957,467, 5,054,828) |
Modified variants (e.g., Fc mutations, glycoengineering) |
| Formulation & delivery |
Sub‑cutaneous (Amgen’s “Humira SC” patents) |
Sub‑cutaneous stability, nanoparticle delivery, inhalation, oral‑delivery attempts |
| Disease indications |
RA, AS, PsA, Crohn’s, UC, etc. |
CNS indications (MS, ALS), pulmonary indications (COPD, asthma) |
| Immunogenicity |
Original ADA mitigation strategies |
New glycoforms, PEGylation, T‑cell epitope deletion |
5. Practical take‑aways
| Scenario |
Recommendation |
| Developing a biosimilar |
Be aware that the original Humira patents are expired (US) but still enforceable in other regions. Beyondspring’s patents may affect “next‑gen” biosimilars. |
| Licensing adalimumab‑like molecules |
Beyondspring’s patents may provide exclusive rights to certain delivery platforms or modified antibodies. |
| Research & development |
If you’re working on a new TNF‑α blocker, avoid overlapping claims by focusing on non‑overlapping sequence or delivery mechanisms. |
| Commercial strategy |
Monitor Beyondspring’s patent expiry schedule to time potential product launches or generic entry. |
6. Where to dig deeper
- USPTO Patent Full-Text & Image Database (PatFT) – Search by assignee “Beyondspring” or by “adalimumab”.
- WIPO PATENTSCOPE – Use “Beyondspring” + “adalimumab” to find international filings (PCT).
- EPO Espacenet – Quick view of European patent families.
- Google Patents – User‑friendly interface with citation networks.
- Patent analytics platforms (e.g., Derwent, LexisNexis) – For commercial intelligence and freedom‑to‑operate reports.
Bottom line
Beyondspring Pharma is not “owning” the original Humira patents, but they hold a growing portfolio of modifications and delivery platform patents built on the adalimumab scaffold. These patents could influence the market for next‑generation anti‑TNF‑α therapies, especially if you’re looking to develop or commercialize a “next‑gen” adalimumab analog. Stay on top of the filing dates, claims, and expiration windows to navigate this crowded space smoothly.